Provider review
SnagRx Tirzepatide Review
Released: · Last reviewed:
SnagRx is reviewed here against a fixed evidence checklist: advertised and all-in tirzepatide pricing, mandatory fees, dose coverage, pharmacy, clinician model and cancellation terms. SnagRx prints $119 (was $349) (read on its own page on October 15, 2026). It is listed but not compared like-for-like: Sale price; plan-length prices are not printed.
Key takeaways
- Printed figure $119 (was $349); not a standing all-in price (Sale price; plan-length prices are not printed).
- Mandatory fees recorded: Medication, supplies, doctor review and shipping stated as included.
- Compounding pharmacy, licence, facility type, clinicians, states, and cancellation terms are all unverified and shown as Verification Pending rather than inferred.
- Compounded tirzepatide is not FDA approved and is not reviewed by the FDA before sale.
| Provider | SnagRx |
|---|---|
| Operating status | Active |
| Program type | Compounded-GLP-1-focused |
| Tirzepatide price (as captured) | $119 (was $349) (read 2026-10-15) |
| Normalised monthly cost | Not comparable: Sale price; plan-length prices are not printed. |
| Mandatory fees | Medication, supplies, doctor review and shipping stated as included |
| Medication included | Stated as included |
| Billing cadence | Monthly (promotional) |
| Compounding pharmacy | Verification Pending |
| Pharmacy licence | Verification Pending |
| Facility type (503A/503B) | Verification Pending |
| Named clinicians | Verification Pending |
| States served | Verification Pending |
| Dose coverage | Verification Pending |
| Shipping terms | Verification Pending |
| Cancellation policy | Verification Pending |
| Refund policy | Verification Pending |
| Auto-renewal terms | Verification Pending |
| Evidence source | Official provider |
| Source confidence | Moderate |
| Price verified | 2026-10-15 |
What is the verdict on this provider?
SnagRx prints a price, but not one this site can compare like-for-like: Sale price; plan-length prices are not printed. That is a comparability limitation, not a judgement about the service.
What does tirzepatide actually cost at SnagRx?
SnagRx prints $119 (was $349) (read on its own page on October 15, 2026). It is listed but not compared like-for-like: Sale price; plan-length prices are not printed.
Source: snagrx.com. Confirm the recurring price after any first month, every mandatory fee and the price at your maintenance dose at checkout before enrolling.
What does the captured source actually state?
| Field | Text as captured from the provider's own page |
|---|---|
| Tirzepatide pricing, as published | $119/month promotion against a displayed $399 list price; no plan totals; no end date stated |
| Semaglutide pricing, as published | $69/month promotion (same structure) |
| Fee structure, as published | Medication, supplies, doctor review and shipping stated as included |
| Medication inclusion, as published | Stated as included |
| Billing cadence, as published | Monthly (promotional) |
| Evidence type | Current public advertised promotional pricing (read 2026-09-04) |
| Capture caveat | LegitScript certification stated and four partner pharmacies named on the site — not verified first-party; promotion end date not stated |
How should the SnagRx pricing structure be read?
SnagRx publishes multi-month or prepaid options alongside any monthly rate. Committed tiers lower the advertised monthly figure but concentrate financial risk: if treatment stops early — and gastrointestinal effects end treatment for a measurable share of people — the money already paid is governed by cancellation and refund terms that are unverified here.
The same source also publishes semaglutide pricing, which is useful context: a provider pricing both drugs allows a switch without changing provider, though the two are not interchangeable and any change is a prescriber decision.
Source confidence for this record is recorded as Moderate, which is why the figures above are presented as captured text rather than asserted as the current price.
What has not been verified?
What should you confirm before enrolling?
- The recurring price after any introductory or first-month rate, in writing.
- Every mandatory fee: membership, consultation, shipping, and any dose-related surcharge.
- Which compounding pharmacy dispenses, its state licence number, and whether it is 503A or 503B.
- What happens to the price when your dose increases.
- The cancellation method, notice period, and whether prepaid months are refundable.
- Whether the plan auto-renews and how to stop it.
- That a licensed clinician reviews your intake and is reachable for side-effect questions.
What are the alternatives?
Primary source: SnagRx pricing page · captured 2026-09-04. LegitScript certification stated and four partner pharmacies named on the site — not verified first-party; promotion end date not stated
| Group | Verified | Required for full review |
|---|---|---|
| Pricing fields held | 2 | 5 |
| Pharmacy fields held | 0 | 4 |
| Policy fields held | 0 | 4 |
Why is this provider not ranked on cost?
| Test | Result for this provider |
|---|---|
| Recurring price stated | Yes |
| Medication included | Stated as included |
| All mandatory fees confirmed | No |
| Classification | from teaser |
| Published reason | Promotional price against a $399 list price; renewal price unverified — not a recurring all-in cost |
What is SnagRx's status after the compounding change?
SnagRx was captured on 2026-09-04 advertising compounded tirzepatide. That capture predates nothing — it is recent — but the legal basis for the product it describes changed before it was taken. Compounding of tirzepatide was permitted only while the drug sat on the FDA shortage list. The shortage was declared resolved on 2 October 2024 and reaffirmed by declaratory order on 19 December 2024, and enforcement discretion ended on 18 February 2025 for 503A pharmacies and 19 March 2025 for 503B outsourcing facilities.
This site records SnagRx's prices with the date each was read and compares them only on a like-for-like basis (see the position table). If SnagRx continues to advertise compounded tirzepatide, the useful question is not whether the price is competitive but what legal basis the product is supplied under and which state-licensed pharmacy dispenses it. Neither is verified in this record.
| Question | Position for SnagRx | How this site treats it |
|---|---|---|
| Was compounded tirzepatide advertised at capture? | Yes | Recorded with its read date |
| Operating status at capture | Active | Reported as captured; not re-verified since |
| Legal basis for continued compounded supply | Not disclosed in the captured source | Verification Pending — not inferred |
| Dispensing pharmacy identity | Not disclosed | Verification Pending |
| Whether approved products are now offered | Not established in this record | Verification Pending — ask the provider directly |
How was SnagRx's pricing classified?
Every provider on this site passes through the same four-part price test before it can appear in a cost ranking. The test asks whether the captured source states a recurring price, whether medication is included in that price, whether every mandatory fee is identified, and whether the figure describes the standard subcutaneous injection rather than an alternative formulation. SnagRx is assessed below against each part in turn.
| Test | Result for this provider | Why it matters |
|---|---|---|
| A recurring price is stated | Yes | $119/month promotion against a displayed $399 list price; no plan totals; no end date stated |
| Medication is included in that price | Stated as included | Determines whether the figure is the whole cost or only part of it |
| Every mandatory fee is identified | Medication, supplies, doctor review and shipping stated as included | A separate recurring membership or care fee changes the real monthly outlay |
| The figure describes the standard injection | not applicable | Microdose, ODT, sublingual and troche preparations are not comparable with an injection |
| Classification result | from teaser | Promotional price against a $399 list price; renewal price unverified — not a recurring all-in cost |
SnagRx does not pass, and the reason is specific: Promotional price against a $399 list price; renewal price unverified — not a recurring all-in cost. This is a statement about disclosure, not about service quality or value. A provider may be excellent and still publish pricing in a form that cannot be normalised — and equally, a provider that publishes a complete price may not be the right choice on any other dimension. The exclusion means only that a like-for-like cost comparison is not currently possible.
How does SnagRx compare with the other programs in our index?
SnagRx is listed in our index with the figure it prints ($119 (was $349)) but is not placed in the standing-price order: Sale price; plan-length prices are not printed. For reference, the 15 programs with standing all-in prices cost $1,368 to $3,640 for twelve months on their cheapest plans (median $2,568).
| # | Program | Lowest monthly | Plan behind it | Month to month | 12-month cost | How the 12 months are bought | Source · read |
|---|---|---|---|---|---|---|---|
| 1 | Mondae | $114 | $114/mo on a prepaid 6-month plan ($684) | $126 | $1,368 | two 6-month plans at $684 | mondae.com · 2026-10-15 |
| 2 | NexLife | $115 | $115/mo on a 12-month plan ($1,380) | $129 | $1,380 | 12-month plan | nexlife.us · 2026-11-06 |
| 3 | TRYM Health | $125 | $125/mo on the 12-month plan ($1,500 one-time payment) | $180 | $1,500 | 12-month one-time payment | trymhealth.com · 2026-11-08 |
| 4 | Eden | $129 | $129 every month | $129 | $1,548 | 12 × $129 | eden.health · 2026-10-15 |
| 5 | Sprout Health | $149 | $149/mo on the 12-month plan ($1,788 up front) | $199/4 wk | $1,788 | 12-month plan billed up front | joinsprouthealth.com · 2026-10-15 |
| 6 | He & She MD | $159 | $159/mo on the 12-month plan | $339 | $1,908 | 12 × $159 | heandshemd.com · 2026-10-15 |
| 7 | Bodybuilding Health+ | $174.67 | $174.67/mo on 6 months | $209 | $2,096 | two 6-month plans | bbhealthplus.com · 2026-10-15 |
| 8 | TelePep | $214 | $214/mo on the annual plan ($2,568 up front) | $249 | $2,568 | annual plan up front | telepeptide.org · 2026-10-15 |
| 9 | Yucca Health | $225 | $225/mo on 6 months ($1,350) | $258 | $2,700 | two 6-month plans | tryyucca.com · 2026-09-04 (carried) |
| 10 | Join Josie | $233.25 | $233.25/mo on 12 months ($2,799) | $349 | $2,799 | 12-month plan | joinjosie.com · 2026-10-15 |
| 11 | Pallas Health | $239 | $239/mo average on the annual plan | $299/4 wk | $2,868 | 12 × $239 average | pallashealth.co · 2026-10-15 |
| 12 | Fridays | $240 | $240/mo on the annual plan (paid annually) | $359 | $2,880 | 12 × $240 | joinfridays.com · 2026-10-15 |
| 13 | Found | $239 | $239 per 4 weeks on the 12-month cash plan | $359/4 wk | $3,107 | 13 cycles × $239 | joinfound.com · 2026-10-15 |
| 14 | Zappy Health | $299 | $299/mo on 6 months ($1,794) | $349 | $3,588 | two 6-month plans | zappyhealth.com · 2026-11-08 |
| 15 | Enhance.MD | $280 | $280 per 4 weeks on the 12-month plan | $329/4 wk | $3,640 | 13 cycles × $280 | enhance.md · 2026-10-15 |
What else does SnagRx's captured record contain?
The full record held for SnagRx is reproduced below. This site publishes the underlying capture rather than only its own summary, so a reader can see exactly what the interpretation rests on and disagree with it if the reading looks wrong.
| Field | Value held for this provider |
|---|---|
| Programme category | Compounded-GLP-1-focused |
| Operating status | Active |
| Tirzepatide pricing, as captured | $119/month promotion against a displayed $399 list price; no plan totals; no end date stated |
| Semaglutide pricing, as captured | $69/month promotion (same structure) |
| Mandatory fees, as captured | Medication, supplies, doctor review and shipping stated as included |
| Medication inclusion | Stated as included |
| Billing cadence | Monthly (promotional) |
| Evidence type | Current public advertised promotional pricing (read 2026-09-04) |
| Capture caveats | LegitScript certification stated and four partner pharmacies named on the site — not verified first-party; promotion end date not stated |
| Source | Official provider |
| Source confidence | Moderate |
| Price verified | 2026-09-04 |
SnagRx's semaglutide pricing is recorded because the relationship between a provider's semaglutide and tirzepatide pricing is informative on its own. Semaglutide is typically the cheaper of the two in this market, and a provider whose tirzepatide premium is unusually large or unusually small relative to its semaglutide rate is worth asking about — it can reflect different pharmacy sourcing, different dose coverage, or a promotional structure that will not persist. For SnagRx the captured semaglutide text reads: $69/month promotion (same structure)
The capture for SnagRx is rated moderate confidence. That rating reflects genuine ambiguity in the source — typically a page that presents a starting figure without stating which dose, formulation, or commitment length it applies to, or that presents different figures on different landing pages. Moderate confidence is why the figure is reported but not ranked.
What should you ask SnagRx before enrolling?
These questions are selected against the specific gaps in SnagRx's record rather than being a generic checklist. Ask them in writing and keep the reply: a verbal assurance from a sales channel is not a contractual term, and terms are what govern a dispute.
- What is the recurring monthly price after any introductory or first-month rate?
- Is the medication itself included in that price, or billed separately?
- Which dose, formulation, and commitment length does the advertised starting price actually apply to?
- What does the same programme cost at a standard maintenance dose rather than the starting tier?
- Which compounding pharmacy prepares the medication, and what is its state licence number?
- Is that pharmacy a 503A compounder or a 503B outsourcing facility?
- Does the price change when the dose increases to 10 mg or 15 mg?
- What concentration is dispensed, in mg/mL, and what beyond-use date is assigned?
- How is the plan cancelled, what notice is required, and are prepaid months refundable?
- Does the plan auto-renew, and how is renewal stopped?
- Which licensed clinician reviews the intake, and how are side-effect questions handled?
A provider that answers all of these in writing has demonstrated something meaningful about how it operates. A provider that will not name its compounding pharmacy before payment has also told you something, and it is worth weighing that refusal as evidence in its own right.
Why is this review shorter than the others?
Because the evidence held for SnagRx does not support more. Its captured pricing (Promotional price against a $399 list price; renewal price unverified — not a recurring all-in cost) cannot be reduced to a comparable recurring figure, and its pharmacy, clinician, states, dose-coverage and cancellation fields are all unverified. Writing further would mean inferring facts rather than reporting them.
This site treats a short page as the correct output in that situation. The alternative — padding a review with general commentary that would read identically for any provider — would give an impression of thoroughness the underlying evidence does not justify, and would make it harder for a reader to see which providers have actually disclosed something. The length of this page is itself a finding.
Current approved-product pathways: Zepbound self-pay from $299 per month at the starting dose. Full pathway comparison.
What do the technical terms on this page mean?
Definitions for the 10 technical terms this page uses, including 503A, 503B, GLP-1, auto-renewal — in the specific sense used above.
| 503A | A pharmacy that compounds patient-specific preparations against individual prescriptions. It is licensed by a state board of pharmacy and is not subject to the same federal manufacturing requirements as a 503B facility. |
|---|---|
| 503B | An outsourcing facility that may compound in larger batches without individual prescriptions. It registers with the FDA and is subject to current good manufacturing practice requirements, though registration is still not product approval. |
| GLP-1 | Glucagon-like peptide-1. An incretin hormone that slows gastric emptying, signals satiety to the brain, stimulates glucose-dependent insulin release, and suppresses inappropriate glucagon secretion. |
| auto-renewal | A term under which a plan renews automatically unless cancelled. Combined with a notice period, it determines how much money is at risk if treatment stops. |
| beyond-use date | The date after which a compounded preparation should not be used. It is assigned by the compounding pharmacy based on its own conditions, and is typically much shorter than a manufacturer expiry date derived from formal stability testing. |
| compounded | Prepared by a pharmacy rather than manufactured under an approved application. Compounded tirzepatide is not FDA approved and has not been evaluated in any randomised trial. |
| effective monthly cost | The recurring amount actually paid each month once every mandatory fee is included. It is frequently higher than the advertised medication price, which is why this site normalises before ranking. |
| membership fee | A recurring charge separate from the medication price, common in telehealth weight programmes. It can add $40 to $80 per month and frequently reverses which provider is genuinely cheaper. |
| mg/mL | Milligrams of drug per millilitre of liquid — the concentration. Two vials containing the same nominal dose can require different injection volumes if their concentrations differ, which is why this site does not publish volume calculations. |
| subcutaneous | Beneath the skin. Tirzepatide is given by subcutaneous injection, usually into the abdomen, thigh, or upper arm. |
Frequently asked questions
How much does tirzepatide cost at SnagRx?
SnagRx prints $119 (was $349) (read on its own page on October 15, 2026). It is listed but not compared like-for-like: Sale price; plan-length prices are not printed. Confirm the recurring price and every mandatory fee at checkout before enrolling.
Which pharmacy does SnagRx use?
Not verified. The compounding pharmacy identity, its state licence, and whether it is a 503A or 503B facility have not been confirmed first-party, so nothing is asserted.
Is SnagRx cheaper than other providers?
Its printed figure ($119 (was $349)) is not a standing all-in price, so this site does not place it in the order: Sale price; plan-length prices are not printed. Ask for the recurring price at a maintenance dose and compare it with our index, where standing plans cost $1,368 to $3,640 for twelve months.
Is compounded tirzepatide FDA approved?
No. Compounded tirzepatide is not FDA approved and is not reviewed by the FDA for safety, effectiveness, or quality before sale.
Sources for this page
Change history
| Date | Change |
|---|---|
| 2026-09-04 | Page published with the 2026-09-04 dataset snapshot; public pricing read first-party on 2026-09-04. |
| 2026-11-08 | Price record updated to the October 15, 2026 read; checklist, verdict, cost section, position table and FAQ answers rebuilt; dated notice added above the older capture. |
Dates change only for substantive edits, never for cosmetic changes. Corrections: corrections policy.